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Abstract 
In the health care business environment ranking, Nigeria is found towards the bottom of the table featuring fourteen 
key countries in the Middle East and Africa (MEA) region.  While Nigeria continues to be considered one of the 
least attractive markets in the region, its potential beyond forecast period is relatively considerable, given the sheer 
population size and its high disease burden.  Nigeria’s healthcare market is forecast to grow to US$1.27 billion in 
2012, thus more than doubling 2007 figure of US$596 million.  Paradigmatic CRM Approach could be a panacea to 
the sales depression in Healthcare Industry in Nigeria, as it represents the most profound and exciting sales 
opportunities in businesses today.  The regression factor score result of this study indicates satisfied significance 
effect of the independent variables of CRM at p = 0.05 level of significance and a corresponding value of F = 
129.925.  This suggests that cross-disciplinary teams should be established from the initiation of the planning stages 
for CRM that require IT and sales managers to work together as well as other functional players like marketing, 
accounting and sales support. 
Keywords: Strategic Alliance; Competitive Environment; Salesforce Automation; Sales Volume Analysis; 
Interactive Marketing; Environmental Scanning; Strategic Window; Strategic Business Units. 
 
Introduction 
The Nigeria pharmaceuticals and Health care report provides independent forecasts and competitive intelligence on 
Nigeria’s pharmaceuticals and health care industry. Nigeria’s drug market remains subdued due to readily available 
counterfeit drugs, poor health care infrasture and the limited spending power of citizens. The market was estimated 
to be worth US$ 278 million in 2007 and it should grow at around 5% year-on-year (y-o-y), reaching US$369 
million by 2012.  Despite the federal government’s efforts to promote domestic manufacturing, Nigeria remains 
heavily reliant on imported pharmaceuticals. The National Drug Policy sets a target for 70% of the country’s demand 
for drugs to be met by local industry. However, in 2007 BMI estimated that imports supplied 54% of the market. On 
the whole, domestic players do not appear ready to manufacture high-tech, so it was expected that imports would 
remain dominant. The domestic drug makers seem to be increasingly looking to diversify into consumer health 
products, most likely in response to the difficult operating environment in the core market. In January 2008, both 
fidson Health care and Neimeth Pharmaceuticals announced they were to launch consumer health lines. Neimeth 
revealed it would do this through two newly created subsidiaries – one concentrating on food and nutraceuticals, the 
other on herbal remedies (Kang, 2009: 28-34). 
Health care, and in particular how to expand access, continues to be a hot topic throughout Africa, with a variety of 
solutions being pursued by national governments – Nigeria’s solution being the National Health Insurance Scheme 
(NHIS). There are encouraging signs for private sector involvement in African health care after the World Bank’s 
International Finance Corporation (IFC) unveiled a US $1 billion support package for the development of private 
health care on the continent. With the NHIS struggling in terms of participant members, BMI believes that 
increasingly popular health saving accounts (HSAs) can provide a solution for citizens unable to benefit from the 
NHIS-Particularly sector. In BMI’s updated Business Environment Rankings, Nigeria remains in 13th place out of 14 
Middle East and Africa (MEA) countries surveyed. Nigeria’s score continues to be held down by a combination of 
low consumer spending power and a weak regulatory environment. Both of these factors should remain in play over 
the forecast period, making it unlikely that Nigeria will overtake Egypt, which is one place ahead. Nigeria’s score in 
the country structure category is more promising, suggesting that there is potential market growth if the previously 
mentioned weaknesses can be remedied. Some of the Nigeria’s pharmaceutical companies mentioned include the 
following: (i) Pfizer; (ii) Novartis; (iii) Sanofi-Aventis; (iv) Glaxo Smithkline (GSK); (v) Nigeria-German Chemicals 
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Plc. (NGC); (vi) Emzor; (vii) Fidson Health care; (viii) Archy; (ix) Neros pharmaceuticals; (x) Drugfield 
Pharmaceuticals Limited; (xi) Campharm products; and (xii) Tyonex. 
 
CRM is a comprehensive business model for increasing revenues and profits by focusing on customers. Many 
companies are now adopting CRM as a mission-critical business strategy. These companies are redesigning internal 
and external business processes and associated information systems with them. Because the focus of CRM is 
aligning the organization’s internal and external systems to be customer – centric, marketing as a discipline becomes 
a core contributor to the success of CRM by virtue of its disciplinary expertise on customers. Specifically, the 
salesforce is a group within most firms that can add substantial value to the success of this process. The salesforce 
can play a pivotal relationship management role. 
 
More sophisticated approaches to data management are a key enabler of CRM. Yet, it is a serious mistake to consider 
CRM as a mere software. In fact, many pharmaceutical firms in Nigeria are struggling with their CRM initiatives 
probably because they have bought the sophisticated software, but do not have the culture, structure, leadership, or 
internal technical expertise to make the initiative successful. The biggest mistake is thinking that CRM is owned by 
the IT people simply because the process is software – driven. But if anyone should own CRM, it should be the 
customer contact team within a firm, which usually means the salesforce. Problems leading to CRM failure often are 
traced to organizational, not software, issues. A recent report from a conference board information group indicates 
that half of the companies’ survey in North America and Europe suggest that lack of salesforce alignment is the 
leading difficulty in CRM implementation (Myers, 2008: 1173-1178).  Salesforce have a key role to play in fostering 
successful relationships. They spend a large amount of time by themselves calling on customers and traveling 
between accounts. This means that most of the time they are away from any kind of support from their peers or 
leaders, and they often feel isolated and detached from their companies. Consequently, they usually could require 
more motivation than is needed for other jobs to reach the performance level management desires. Salespeople can 
also be fiercely independent. Particularly, very successful salespeople may balk at changing their customer approach 
substantively when their interests are not integrated into the system. This potential pitfall of CRM implementation, if 
not properly addressed, can be devastating to a firm financially, operationally, and culturally. As stated earlier that if 
a CRM system fails, the first place to look is not within the software but within the ranks of management. This gave 
rise to the importance of this study, which was to examine the impact of a salesforce motivation on effective 
implementation of a CRM strategy in the pharmaceutical and healthcare industry in Nigeria. 
 
Literature Search 
The earliest drugstores date back to the middle ages. The first known drugstore was opened by Arabian pharmacists 
in Baghdad in 754 AD, and many more soon began operating throughout the medieval Islamic world and eventually 
medieval Europe. By the nineteenth century, many of the drug stores in Europe and North America had eventually 
developed into larger pharmaceutical companies. Most of today’s major pharmaceutical companies were founded in 
the late nineteenth and early twentieth centuries. Key discoveries of the 1920s and 1930s, such as insulin and 
penicillin, became mass-manufactured and distributed. Switzerland, Germany and Italy had particularly strong 
industries, with the UK, US, Belgium and Netherlands following suit. Legislation was enacted to test and approve 
drugs and to require appropriate labeling. Prescription and non-prescription drugs become legally distinguished from 
one another as the pharmaceutical industry matured. The industry got underway in earnest from the 1950s, due to the 
development of systematic scientific approaches, understanding of human biology (including DNA) and 
sophisticated manufacturing techniques (Robinson, 2008: 579-585). 
 
Numerous new drugs were developed during the 1950s and mass-produced and marketed through the 1960s. These 
included the first oral contraceptive, “The Pill”, cortisone, blood-pressure drugs and other heart medications. MAO 
inhibitors, chlorpromazine (Thorazine), Haldol (Haloperidol) and the tranquilizers ushered in the age of psychiatric 
medication. Valium (diazepam), discovered in 1960, was marketed from 1963 and rapidly became the most 
prescribed drug in history, prior to controversy over dependency and habituation. Attempts were made to increase 
regulation and to limit financial links between companies and prescribing physicians, including by the relatively new 
US FDA. Such calls increased in the 1960s after the thalidomide tragedy came to light, in which the use of a new 
tranquilizer in pregnant women caused severe birth defects. In 1964, the world medical Association issued its 
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Declaration of Helsinki, which set standards for clinical research and demanded that subjects give their informed 
consent before enrolling in an experiment. Pharmaceutical companies became required to prove efficacy in clinical 
trials before marketing drugs. Cancer drugs were a feature of the 1970s. From 1978, India took over as the primary 
centre of pharmaceutical production without patent protection (Sharfstein 2005: 27-29). 
 
The industry remained relatively small scale until the 1970s when it began to expand at a greater rate. Legislation 
allowing for strong patents, to cover both the process of manufacture and the specific products came in force in most 
countries. By the mid-1980s, small biotechnology firms were struggling for survival, which led to the formation of 
mutually beneficial partnerships with large pharmaceutical companies and a host of corporate buyouts of the smaller 
firms. Pharmaceutical manufacturing became concentrated, with a few large companies holding a dominant position 
throughout the world and with a few companies producing medicines within each country. The pharmaceutical 
industry entered the 1980s pressured by economics and a host of new regulations, both safety and environmental, but 
also transformed by new DNA chemistries and new technologies for analysis and computation. Drugs for heart 
disease and for AIDS were a feature of the 1980s, involving challenges to regulatory bodies and a faster approval 
process. Managed care and Health Maintenance Organizations (HMOs) spread during the 1980s as part of an effort 
to contain rising medical costs, and the development of preventative and maintenance medications became more 
important. A new business atmosphere became institutionalized in the 1990s, characterized by mergers and 
takeovers, and by a dramatic increase in the use of contract research organizations for clinical development and even 
for basic R&D. The pharmaceutical industry confronted a new business climate and new regulations, born in part 
from dealing with world market forces and protests by activities in developing countries. Animal right activism was 
also a problem (Ray, 2003: 1182-1193). 
 
Marketing changed dramatically in the 1990s, partly because of a new consumerism. The internet made possible the 
direct purchase of medicine by drug consumers and of raw materials by drug producers, transforming the nature of 
business. In the US, Direct-to-Consumer Advertising proliferated on radio and television because of new FDA 
regulations in 1997 that liberalized requirements for the presentation of risks. The new antidepressants, the SSRIs, 
notably fluoxetine (Prozac), rapidly became bestsellers and marketed for additional disorders. Drug development 
progressed from a hit-and-miss approach to rational drug discovery in both laboratory design and natural-product 
surveys. Demand for nutritional supplements and so-called alternative medicines created new opportunities and 
increased competition in the industry. Controversies emerged around adverse effects, notably regarding Vioxx in the 
US, and marketing tactics. Pharmaceutical companies became increasingly accused of disease mongering or over-
medicalizing personal or social problems. There are now more than 200 major pharmaceutical companies, jointly 
said to be more profitable than almost any other industry, and employing more political lobbyists than any other 
industry. Advances in biotechnology and the human genome project promise ever more sophisticated, and possibly 
more individualized, medications (Tungaraz and Poole, 2007: 82-83). 
 
Pharmaceutical companies commonly spend a large amount on advertising, marketing and lobbying. In the US, drug 
companies spend $19 billion a year on promotion. Advertising is common in health care journals as well as through 
more mainstream media routes. In some countries, notably the US, they are allowed to advertise direct to the general 
public. Pharmaceutical companies generally employ salespeople (often called “drug reps” or, an older term, “detail 
men”) to market directly and personally to physicians and other health care provider. In some countries, notably the 
US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the 
US is regulated by the Federal Prescription Drug Marketing Act of 1987. Physicians, physician assistants, and nurse 
practitioners are perhaps the most important players in pharmaceutical sales because they write the prescriptions that 
determine which drugs will be used by the patient. Influencing the physician is often seen as the key to prescription 
of pharmaceutical sales. A medium-sized pharmaceutical company might have a salesforce of 1000 representatives. 
The largest companies have tens of thousands of representatives. Currently, there are approximately 100,000 
pharmaceutical sales reps in the United Sates lobbying some 120,000 pharmaceutical prescribers. The number 
doubled in the four years from 1999 to 2003. Drug companies spend $5 billion annually sending representatives to 
physicians’ offices. Pharmaceutical companies use the service of specialized health care marketing research 
companies to perform marketing research among physicians and other health care professionals (Moyniha, 2008: 
1163; Myers, 2008: 1169-1172; Mackenzie, 2006: 27-35; Solenke, 2008: 22). 
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Private insurance or public health bodies (e.g. the NHS in the UK) decide which drugs to pay for, and restrict the 
drugs that can be prescribed through the use of formularies. Public and private insurers restrict the brands, types and 
number of drugs that they will cover. Not only can the insurer affect drug sales by including or excluding a particular 
drug from a formulary, they can affect sales by tiering or placing bureaucratic hurdles to prescribing certain drugs as 
well. In January 2006, the US government instituted a new public prescription drug plan through its medicare 
program known as Medicare Part D. This program engages private insurers to negotiate with pharmaceutical 
companies for the placement of drugs on tried formularies. Commercial stores and pharmacies are a major target of 
non-prescription sales and marketing for pharmaceutical companies. Since the 1980s new methods of marketing for 
prescription drugs to consumers have become important. Direct – to – consumer media advertising was legalized in 
the FDA Guidance for Industry on Consumer-Directed Broadcast Advertisements (Healy, 2007: 42-49). 
 
There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been 
accusations and findings of influence on doctors and other health professionals through drug reps, including the 
constant provision of marketing “gifts” and biased information to health professionals, highly prevalent advertising 
in journals and conferences; funding independent health care organizations and health promotion campaigns; 
lobbying physicians and politicians (more than any other industry in the US; sponsorship of medical schools or nurse 
trainings; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as 
paid consultants on medical advisory boards. To help ensure the status quo on US, drug regulation and pricing, the 
pharmaceutical industry has thousands of lobbyists in Washington, DC that lobby congress and protect their 
interests. The pharmaceutical industry spent $855 million, more than any other industry, on lobbying activities from 
1998 to 2006, according to the Non-partisan center for Public Integrity. Some advocacy groups, such as No Free 
Lunch, have criticized the effect of drug marketing to physicians because they say it biases physicians to prescribe 
the marketed drugs even when others might be cheaper or better for the patient. There have been related accusations 
of disease mongering (over-medicalizing) to expand the market for medications. An inaugural conference on that 
subject took place in Australia in 2006. A 2005 review by a special committee of the UK Government came to all the 
above conclusions in a European Union context, while also highlighting the contributions and needs of the industry 
(Wise, 2003: 1163:1170). 
 
There is also huge concern about the influence of the pharmaceutical industry on the scientific process. Meta-
analyses have shown that studies sponsored by pharmaceutical companies are several times more likely to report 
positive results, and if a drug company employee is involved (as is often the case, often multiple employees as co-
authors and helped by contracted marketing companies) the effect is even larger. Influence has also extended to the 
training of doctors and nurses in medical schools, which is being fought (Uduji; 2006: 192-199). It has been argued 
that the design of the diagnostic and statistical manual of mental disorder and the expansion of the criteria represents 
an increasing medicalization of human nature, or “disease mongering”, driven by drug company influence on 
psychiatry. The potential for direct conflict of interest has been raised, partly because roughly half the authors who 
selected and defined the DSM-IV psychiatric disorders had or previously had financial relationships with the 
pharmaceutical industry. The president of the organization that designs and publishes the DSM, the American 
Psychiatric Association, recently acknowledged that in general, American psychiatry has “allowed the biopsycho – 
social model to become the bio-bio-bio model” and routinely accepted “kick backs and bribes” from pharmaceutical 
companies (Moynihan and Cassels, 2005). 
 
The role of pharmaceutical companies in the developing world is a matter of some debate, ranging from those 
highlighting the aid provided to the developing world, to those critical of the use of the poorest in human clinical 
trials, often without adequate protections, particularly in states lacking a strong rule of law. Other criticisms include 
an alleged reluctance of the industry to invest in treatments of diseases in less economically advanced countries, such 
as malaria; criticism for the price of patented AIDs medication, which could limit the rapeutic options for patients in 
the third world, where the most people have AIDs. In September 2008, the Open Source Drug Discovery Network 
Was launched in India to combat infectious diseases common to developing countries (Keng, 2009: 28-34). 
Market Leaders in Terms of Revenue: The following is a list of the 20 largest pharmaceutical and biotech 
companies ranked by health care revenue as of 2007. Some companies (eg. Bayer, Johnson & Johnson and Procter & 
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Gamble) have additional revenue not included here. The phrase Big Pharma is often used to refer to companies with 
revenue in excess of $3 billion, and/or R & D Expenditure in excess of $500 million. Table 1 ranked the 20 largest 
pharmaceutical and biotech companies and follows: 
Table 1: 20 largest Pharmaceutical and Biotech companies  
Rank Company Country Revenues 
($millions) 
R & D 
($Millions) 
Net Income 
($millions) 
Employees 
1. Novartis  Switzerland 53,324 7,125 11,053 138,000 
2. Ptizer USA 48,371 7,599 19,337 122,200 
3. Bayer Germany 44,200 1,791 6,450 106,200 
4. Glaxosmithkline UK 42,813 6,373 10,135 106,000 
5. Johnson & Johnson USA 37,020 5,349 7,202 102,695 
6. Sanofi-Aventis  France 35,645 5,565 5,033 100,735 
7. Hoffmann-La Roche Switzerland 33,547 5,258 7,318 100,289 
8. Astra Zeneca UK/Sweden 26,475 3,902 6,063 98,000 
9. Merck & Co. USA 22,636 4,783 4,434 74372 
10. Abbott Laboratories  USA 22,476 2,255 1,717 66,800 
11. Wyeth USA 20,351 3,109 4,197 66,663 
12. Bristol-Myers Squibb USA 17,914 3,067 1,585 60,000 
13. Elililly & Company USA 15,691 3,129 2,663 50,060 
14. Amgen USA 14,268 3,366 2,950 48,000 
15. Boehringer Ingelheim Germany 13,284 1,977 2,163 43,000 
16. Schering-Plough USA 10,594 2,188 1,057 41,500 
17. Baxter International USA 10,378 614 1,397 38,428 
18. Taked a Pharmaceutical 
Co. 
Japan 10,284 1,620 2,870 15,000 
19. Genentech USA 9,284 1,773 2,113 33,500 
20. Procter & Gamble  USA 8,964 NA 10,340 29,258 
Source: Tungaraza, T (2008) “IMS Health Forecasts Growth for Global Pharmaceutical Market” British Medical 
Journal, Volume 36, issue 7400: 1193-1194. 
Market Leaders in Terms of Sales: The top ten pharmaceutical companies by 2007 sales are shown in table 2.  
Table 2: Top Ten Pharmaceutical Companies 
Rank Company Sales ($millions) Growth 
(%) 
Market share 
(%) 
Headquarter 
Location 
1. Pfizer  45,983 2.1 7.3 USA 
2. Glaxo Smithkline 37,034 9.7 5.9 UK 
3. Sanofi-Aventis 35,638 5.0 5.7 France 
4. Novartis 28,880 18.0 4.6 Switzerland 
5. Hoffmann-La Roche 26.596 21.8 4.2 Switzerland  
6. Astra Zeneca 25,741 10.5 4.1 UK/Sweden 
7. Johnson & Johnson 23,267 4.2 3.7 USA 
8. Merck & Co. 22,636 2.8 3.6 USA 
9. Wyeth 15,683 2.4 2.5 USA 
10. Elililly & Company 14,814 7.5 2.4 USA 
Source:  Myers, D (2008) “Changing the Face of Detailing by Motivating Physicians to see Pharmaceutical Sales 
Reps” British Medical Journal, volume 326, issue 7400: 1169. 
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Research Method 
The target population of the study included the grand total (624), of the salesforce size of the top ten pharmaceutical 
and health care companies in Nigeria. These domestic drug makers constitute the population of the study. They 
formed the Big Parmas table below. 
 
Table 3 The Big Pharmas in Nigeria  
Rank Company Senior sales 
Executives 
(Managers 
& above) 
Sales 
Executives 
(Drug Reps 
& others) 
Total 
salesforce 
size  
1. Neimeth International Pharmaceuticals Plc. (Former Pfizer 
Product Plc.) Ikeja Industrial Estate, Lagos 
 
15 
 
91 
 
106 
2. Glaxo-Smithkline Plc. (Merger of Glaxo-Welcome and 
Smithkline Beecham Plc) Creek Road, Apapa, Lagos. 
 
11 
 
87 
 
98 
3. May and Baker Plc, Ikeja Industrial Estate, Lagos. 9 65 74 
4. Evans Medical Plc. Agbara, Avenue. Ikeja Industrial Estate 5 43 48 
5. Roche Nig. Ltd, Dopemu, Agege, Lagos. 6 54 60 
6. SKG-Pharma Ltd, Oba Akran Avenue. Ikeja Industrial Estate. 5 45 50 
7. Novartis Nig. Ltd. (Former Swiss Nigeria Chemical Company 
Ltd) Agege Motor Rd, Mushin, Lagos. 
 
5 
 
43 
 
48 
8. Emzor Pharmaceutical Industries Ltd. Aswani Market Road, 
Isolo, Lagos. 
5 38 43 
9. Ranbaxy Nig. Ltd, (Former Ranbaxy Laboratories Nig. Ltd.) 
Isolo Industrial Estate, Lagos 
 
4 
 
37 
 
41 
10. Fidson Health Care Plc Oregun, Industrial Estate, Lagos. 4 34 38 
Source: Field Survey 
These drug Companies that constitute the population of the study, spend Millions of naira annually sending 
representatives to physician offices to stimulate sales. They spend millions of naira also on the service of specialized 
health care marketing research companies to perform marketing research among physicians and other health care 
professionals. The sample sizes were determined to be 244, using the Yamani (1964:280) formula, while the 
stratified sampling technique was used to ensure a fair representation of the ranked top ten pharmaceutical and health 
care companies in the ratio of 10: 9: 8: 7: 6: 5: 4: 3: 2: 1, using proportionality formula.  The items were selected in 
the ratio of one senior sales executive to three sales executives from each company. This offered a good 
representation of all the segments in the population of the study. Each respondent from the stratum was selected in 
order of their years of experience in the sales job. 
 
Results and Discussion 
The second objective of this study was to examine if CRM strategy is effectively implemented in the pharmaceutical 
and health care industry in Nigeria. In order to get this information, the respondents were asked to rate the following 
factors of a CRM strategy as contained in table 4 based on the extent in which it is practiced by their organizations, 
in a scale of answers from 5 = very high to 1 = Not at all. The results obtained were judged based on the table of 
means of 3 as shown in table 4.3. It was hypothesized that CRM strategy is not effectively implemented in the 
pharmaceutical and health care industry in Nigeria.  
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Table 4: Descriptive Statistics Showing Means Responses of Respondents on the Extent of CRM Practices in 
the Organizations. 
S/N Elements Total Minimum Maximum Mean Std. Dev. Remark 
1. Acquires and captures customer data based on 
Interaction 
178 1 4 2.03 .667 Low 
2. Uses of technology to store and integrate customer 
data 
178 1 4 2.29 .873 Low 
3. Analyzes data for profitable/Unprofitable 
Segments 
178 1 4 2.02 .863 Low 
4. Leverages and disseminates customer information 
through the organization. 
178 1 3 2.33 .742 Low 
5. Customizes its product and service offering based 
on data generated through interactions between the 
customer and the organization. 
178 1 3 2.15 .673 Low 
6. Centralizes and shares learned information from 
customers in order to enhance the relationship 
between customers and the organization. 
178 1 3 2.16 .801 Low 
7. Delegates authority to solve customers’ problem 
quickly- usually by the first person that the 
customer notifies regarding the problem. 
178 1 5 2.11 .806 Low 
8. Operates a logistic system that reacts to, monitors, 
and controls the interaction between the customer 
and the organization. 
178 1 3 1.88 .756 Very 
Low 
9. Uses web vehicles for communications between 
customers and the organization  
178 1 4 1.90 .862 Very 
Low 
10. Operates a central repository for data from various 
functional areas of the organization that are stored 
and inventoried on a centralized computer system 
so that the information can be shared across all 
functional departments of the organization. 
178 1 4 2.15 .951 Low 
11. Develops Product or service offerings customized 
for appropriate customer segment and then pricing 
and communicating these offerings for the purpose 
of enhancing customer relationships. 
178 1 4 2.31 .795 Low 
12. Designs its program to optimize profitability, 
revenue, and customer satisfaction by focusing on 
highly defined and precise customer group. 
178 1 4 2.51 .832 Low 
13. Mseca 178 1.00 3.25 2.1522 .56065 Low 
Source: Analysis of Field Data, 2010 
 
Table 4 shows the descriptive statistics indicating the mean responses of respondents on the extent of CRM practices 
in the pharmaceutical and health care industry in Nigeria. The results were obtained by judgment based on the means 
of 3 as observed in table 4.3. This implies that even though that many of the components underlying CRM system 
are evident in these organizations, yet they are not particularly effectively implemented, integrated and cross-
functional. This suggests that what has changed in the environment to allow for the more integrated approach to 
customers represented by gadgets and equipments is technology. More sophisticated approaches to data management 
are key components and enablers a CRM strategy, yet it is a serious mistake to consider CRM as mere software. 
Consequently, many firms are struggling with their CRM initiatives precisely because they have bought the 
sophisticated software, but do not have the culture, structure, leadership, or internal technical expertise to make the 
initiative successful. Software solutions are just one component of a successful CRM initiative. Companies should 
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approach customer relationship management as a complete business strategy, in which people, processes and 
technology should be organized around delivering superior value to customer.  
 
Nnabuko and Uduji (2008: 113-124) suggested some implementation qualities that successful CRM system should 
share: (i) CRM should be results driven. It is important that the firm decide on specific goals and benefits before 
attempting to implement a CRM strategy; (ii) CRM should be implemented from the top down. The CEO and senior-
level executives must be committed to changing the firm to a new focus on customer; (iii) CRM requires investment 
in training. Firms do not nurture customer relationships, but their people do. Training must be company-wide so that 
everyone knows that the firm is transforming itself. Training must also upgrade the skill sets of employees so that 
they are able to handle new tools; (iv) they communicate effectively across functions. Effective CRM depends on 
cross-disciplinary teams that work together to solve customer problems. It shouldn’t make any difference whether 
the customer interacts with the company directly through the salesforce, over the web, or indirectly through a reseller 
(or is accessing these entire channels simultaneously); (v) they are streamlined. A concentrated focus on the 
customers allows firms to weed out wasteful business practices. If any function or process does not help the firm 
better serve its customers, it probably is not necessary. Streamlining also eliminates the need for costly customization 
when it comes to creating software solutions; (vi) CRM implementation requires involvement of the end users in 
creation of software solutions. Input from employees, suppliers, distributors, and any other partner who will use the 
system is essential. It will not only ensure that the systems meet the needs of all those who will implement them, but 
will encourage everyone to support the transition to customer relationship managements; and (vii) they constantly 
seek improvement. By tracking and measuring results, firms are able to continuously improve relationships with 
customers. And once this groundwork has been laid, technology solutions drive the firms toward a clear 
understanding of each customer and his or her needs. 
 
Table 5: T-Test Showing Independent Sample Test. 
  
Levene's Test 
for Equality 
of Variances 
t-test for Equality of Means 
  
 
95% 
Confidence 
Interval of the 
Difference 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference Lower Upper 
acquires and captures 
customers data based 
on interaction 
Equal variances assumed 174.759 .000 -
11.946 
185 .000 -.711 .059 -.828 -.593 
Equal variances not 
assumed 
  
-5.985 37.000 .000 -.711 .119 -.951 -.470 
uses technology to 
store and integrate 
customer data 
Equal variances assumed 363.095 .000 -6.397 185 .000 -.447 .070 -.585 -.309 
Equal variances not 
assumed 
  
-3.205 37.000 .003 -.447 .140 -.730 -.165 
analyzes data for 
profitable/unprofitable 
segments 
Equal variances assumed 326.096 .000 -8.802 185 .000 -.632 .072 -.773 -.490 
Equal variances not 
assumed 
  
-4.410 37.000 .000 -.632 .143 -.922 -.341 
pass on information 
about the customer 
Equal variances assumed 439.231 .000 -9.505 185 .000 -.500 .053 -.604 -.396 
Equal variances not 
assumed 
  
-4.762 37.000 .000 -.500 .105 -.713 -.287 
customize is product 
and service offering 
Equal variances assumed 312.772 .000 -
13.584 
185 .000 -.684 .050 -.784 -.585 
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based on data 
generated 
Equal variances not 
assumed 
  
-6.806 37.000 .000 -.684 .101 -.888 -.481 
centralized and shares 
learned information 
from customer 
Equal variances assumed 517.226 .000 -
12.719 
185 .000 -.684 .054 -.790 -.578 
Equal variances not 
assumed 
  
-6.372 37.000 .000 -.684 .107 -.902 -.467 
delegates authority to 
solve customer 
Equal variances assumed 350.564 .000 -
11.385 
185 .000 -.711 .062 -.834 -.587 
Equal variances not 
assumed 
  
-5.704 37.000 .000 -.711 .125 -.963 -.458 
operetes a logistic 
system that react to 
monitors and controls 
Equal variances assumed 163.325 .000 -
15.204 
185 .000 -.974 .064 -1.100 -.847 
Equal variances not 
assumed 
  
-7.617 37.000 .000 -.974 .128 -1.233 -.715 
uses web vehicles for 
communication 
between customers 
Equal variances assumed 239.893 .000 -
11.916 
185 .000 -.895 .075 -1.043 -.747 
Equal variances not 
assumed 
  
-5.970 37.000 .000 -.895 .150 -1.198 -.591 
operates a central 
repository for data 
from various functional 
areas 
Equal variances assumed 402.436 .000 -8.377 185 .000 -.658 .079 -.813 -.503 
Equal variances not 
assumed   
-4.197 37.000 .000 -.658 .157 -.976 -.340 
develops product or 
service offerings 
customized 
Equal variances assumed 266.269 .000 -5.648 185 .000 -.342 .061 -.462 -.223 
Equal variances not 
assumed 
  
-2.830 37.000 .007 -.342 .121 -.587 -.097 
designs its program to 
optimize profitability 
Equal variances assumed 151.765 .000 -3.496 185 .001 -.211 .060 -.329 -.092 
Equal variances not 
assumed 
  
-1.751 37.000 .088 -.211 .120 -.454 .033 
Mseca Equal variances assumed 127.397 .000 -
18.224 
185 .000 -.62061 .03405 -
.68780 
-
.55343 
Equal variances not 
assumed 
  
-9.131 37.000 .000 -.62061 .06797 -
.75834 
-
.48289 
Source: Analysis of Field Data, 2010 
Data in table 5 shows that salesperson has a role to play in the stage of relationship expansion, which is marked by 
the opportunity to sell new products or increase the share of the account’s business. Trust is developing, allowing the 
motivated salesperson to focus on identifying additional needs and recommending solutions. Several strategies, 
including generating repeat sales, cross-selling, and full-line selling, may be used to expand business with current 
accounts and move them toward loyalty and long-term commitment to the relationship. In some situations, the most 
appropriate strategy is to generate repeat orders, particularly for supply items and other operating needs. Generating 
repeat sales requires recognizing buying cycles and being present at buying time. Upgrading is convincing the buyer 
to use a higher-quality product or newer product and is similar to generating repeat sales. The buyer selects the 
upgrade because it meets needs better or more efficiently than did old product.  
 
Selling the entire line of associated products is called full-line selling. Many pharmaceutical companies will try to 
get that foot in the door with any sale in order to prove their company’s worth as a supplier. The hope is that the drug 
buyer will want to purchase the full line after trying the company out. Full-line selling is not the same as full-line 
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forcing, a practice used when a company has one top-selling product that it sells through distributors. Full-line 
forcing occurs when the pharmaceutical company forces distributors to carry the full line in order to be able to sell 
the top seller. Full-line selling is a sales strategy that involves leveraging the relationship in order to sell the entire 
line of products. Full-line forcing is a questionable sales tactic, one that got Neimeth Pharmaceutical a great deal of 
negative publicity when they tried to force their distributors into carrying all their product lines. In contrast, full-line 
selling is a legitimate method of strengthening the relationship. Cross-selling is similar to full-line selling but reflects 
selling products that may not be related. Cross-selling works best when the motivated salesperson can leverage the 
existing relationship with the drug buyer. Trust in the salesperson and the selling organization already exists, 
therefore the sale should not be as difficult if the proper needs exist. If the drug buying centre for the second product 
line changes greatly, cross-selling becomes more like the initial sale. 
 
Summary of the Major Findings 
The major findings of this study include the following: 
1. Most of the health care firms in Nigeria are not result driven, and have not decided on specific goals and 
benefits before attempting to implement the CRM strategy. 
2. The CEO and senior-level executives of these firms are not committed to changing the health care firms in 
Nigeria to a new focus on customers as the CRM are not implemented from the top down. 
3. Training to upgrade the skill sets of employees are not companywide, as everyone does not know that the 
health care firms in Nigeria are transforming themselves.  
4. The organizations do not communicate effectively across functions to solve customers’ problems, as most 
of the firms don’t depend on cross-disciplinary teams that work together.  
5. Most of the health care firms in Nigeria are not streamlined, as they do not have a calculated focus on the 
customers that will allow the firms to weed out wasteful business practices that do not help them better 
serve their customers. 
6. Some of the healthcare firms in Nigeria do not involve end users in creation of their software solutions, as 
input from employees, suppliers, distributors, and other partners that would use the system are not 
encouraged.  
7. The health care firms in Nigeria, often do not constantly seek improved relationships with customers as they 
don’t track and measure the result of their CRM strategy.  
 
Conclusion 
Based on the findings of this research, the following major conclusions are made: 
1. It is important that health care firms in Nigeria decide before attempting to implement a CRM strategy to 
improve sales performance in the industry. 
2. The CEO and senior-level executives must be committed to changing the firm to a new focus on customers 
to improve sales performance in the industry 
3. Training must be companywide so that everyone knows that the firm is transforming itself to improve sales 
performance in the industry. 
4. The firm must communicate effectively across functions to improve sales performance in the industry. 
5. A concentrated focus on the customers allows firms to weed out wasteful business practices and improve 
sales performance in the industry. 
6. Input from employees, suppliers, distributors, and any other partners who will use the systems is essential to 
improve sales performance in the industry. 
7. By tracking and measuring results, health care firms are able to continually improve relationships with 
customers to improve sales performance in the industry. 
 
Recommendation  
Based on the findings and conclusions of this research, the following recommendations are made as the panacea to 
sales depression in the health care industry in Nigeria: 
1. They should be result driven. It is important the firm decides on specific goals and benefits before 
attempting to implement a CRM strategy to improve sales  
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2. The investment in training and the training should be companywide so that everyone knows that the firm is 
transforming itself. Training should also be to upgrade the skill sets of employees so that they should be 
able to handle new tools.  
3. They should communicate effectively across functions. It should not make any difference whether the 
customer interacts with the company directly through the sales force, over the web, or indirectly through a 
reseller or is even accessing all of these channels simultaneously.  
4. They should streamline business practices, as concentrated focus on customers would allow focus to weed 
out wasteful business practices. And if any function or process does not help the firm better serve its 
customers, it is probably not necessary at all. Streamlining should enable the firms to eliminate the need for 
costly customization when it comes to creating software solution.  
5. The paradigmatic CRM approach that can cure sales depression in the health care industry should be 
implemented from the top down. The CEO and other senior-level executives should be totally involved and 
committed to changing the firm to a new focus on customers. 
6. Firms should involve end users in creation of software solutions. Input from employees, suppliers, 
distributors, and any other partners who will use the system is essential. Management should not only 
ensure that the systems meet the needs of all those who will implement them but should also encourage 
everyone to support the transition to customer relationship management approach.  
7. Firms seeking to cure sales depression should constantly seek improvement in the business. And by tracking 
and measuring results of performances, firms should be able to continually improve relationships with 
customers.  
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